|
|
 |
|
|
|
|
94. G. S. Burill. Emerging trends: 1994 first quarter update. BioPharm 7: 22, June 1994. |
|
|
|
|
|
|
|
|
95. G. S. Burill. Challenging conventional wisdom: projecting biotech's future. BioPharm 7: 48, November 1994. |
|
|
|
|
|
|
|
|
96. M. M. Canan. Companies refocusing R&D as health debate begins. Pharmaceutical Daily 1: 1, September 24, 1993. |
|
|
|
|
|
|
|
|
97. National Task Force on AIDS drug development to survey industry on drug discovery; Stumbling blocks include funding, staffing issues. FDC ReportsThe Pink Sheet 56: 10, June 27, 1994. |
|
|
|
|
|
|
|
|
98. W. Tucker. Health plans chilling effect on biotech. The Washington Times, July 11, 1994. |
|
|
|
|
|
|
|
|
99. W. L. Thompson. Role of Portfolio Analysis in Corporate Strategic Decisions: New Economics of Health Care Worldwide. Portfolio Management '95. Barnett & Parexel, Aston, PA, 1995. |
|
|
|
|
|
|
|
|
100. M. M. Rumore. The decline in new drug development. Amer. Pharm. 32: 73, 1992. |
|
|
|
|
|